Novabay Pharmaceuticals Inc (NBY)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Novabay Pharmaceuticals Inc chart...

About the Company

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

CEO

Justin Hall

Exchange

NYSE MKT LLC

Website

http://novabay.com/

$23M

Total Revenue

56

Employees

$1M

Market Capitalization

-0.44

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NBY News

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

5d ago, source:

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare ...

NovaBay Pharmaceuticals Inc.

4d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

5h ago, source:

Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular ...

Which Is a Better Investment, Apellis Pharmaceuticals Inc or Avidity Biosciences Inc Stock?

6d ago, source: American Association of Individual Investors

Learn more about whether Apellis Pharmaceuticals Inc or Avidity Biosciences Inc is a better investment based on AAII's A+ ...

Marinus Pharmaceuticals: Q4 Earnings Snapshot

14d ago, source: SFGate

RADNOR, Pa. (AP) — RADNOR, Pa. (AP) — Marinus Pharmaceuticals Inc. (MRNS) on Tuesday reported a loss of $41.8 million in its fourth quarter. The Radnor, Pennsylvania-based company said it had a loss ...

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

1mon ago, source:

Detailed price information for Sonoma Pharmaceuticals Inc (SNOA-Q) from The Globe and Mail including charting and trades.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...